
JNJ Stock Forecast & Price Target
JNJ Analyst Ratings
Bulls say
Johnson & Johnson's stock outlook is positively influenced by the company's robust performance, with total sales reaching $24.06 billion, surpassing both Stifel and Consensus projections, largely driven by growth in Innovative Medicine and MedTech segments. The anticipated separation of the Orthopaedic business is expected to enhance capital allocation, leading to increased investment in research and development and improved growth opportunities within MedTech, particularly in the cardiovascular and vision sectors. Furthermore, updated revenue estimates indicate a promising trajectory, with projections for 2026 now set at $100.42 billion, underscoring the company's strong operational growth dynamics and strategic adjustments to capitalize on high-potential therapies.
Bears say
Johnson & Johnson faces multiple fundamental challenges that contribute to a negative outlook on its stock, including the anticipated lower organic revenue growth due to decreased contributions from its pharmaceutical pipeline and the impending loss of exclusivity for key drugs. The company's MedTech division is projected to experience slower growth due to competitive pressures and the risks associated with product uptake, particularly in robotic-assisted surgery. Additionally, ongoing litigation and settlement costs, coupled with potential difficulties in integrating acquisitions, further complicate JNJ's financial stability and investor confidence.
This aggregate rating is based on analysts' research of Johnson & Johnson and is not a guaranteed prediction by Public.com or investment advice.
JNJ Analyst Forecast & Price Prediction
Start investing in JNJ
Order type
Buy in
Order amount
Est. shares
0 shares